• 1
    Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007; 57: 43-66.
  • 2
    Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004; 291: 2720-2726.
  • 3
    Du W, Gadgeel SM, Simon MS. Predictors of enrollment in lung cancer clinical trials. Cancer. 2006; 106: 420-425.
  • 4
    de Cos Escuin JS, Vecentea CD, Penafiel JC, Miranda JAR, Gonzalez MAS, Jimenez JFM. Overall long-term survival in lung cancer analyzed in 610 unselected patients. Arch Bronconeumol. 2004; 40: 268-274.
  • 5
    Fry WA, Phillips JL, Meck HR. Ten-year survey of lung cancer treatment and survival in hospitals in the United States. Cancer Invest. 1999; 86: 1867-1876.
  • 6
    Paulson DL, Urschel HC. Selectivity in the surgical treatment of bronchogenic carcinoma. J Thorac Cardiovasc Surg. 1971; 62: 554-562.
  • 7
    Pearson FG, DeLarue NC, Ilves R, et al. Significance of positive superior mediastinal nodes identified at mediastinoscopy in patients with resectable cancer of the lung. J Thorac Cardiovasc Surg. 1982; 83: 1-11.
  • 8
    Naruke T, Goya T, Tsuchiya R, et al. The importance of surgery to non-small cell carcinoma of the lung with mediastinal lymph node metastasis. Ann Thorac Surg. 1988; 46: 603-610.
  • 9
    Watanabe Y, Shimizu J, Oda M, et al. Results of surgical treatment in patients with stage IIIA non-small-cell lung cancer. Thorac Cardiovasc Surg. 1991; 39: 44-49.
  • 10
    Izbicki JR, Passlick B, Pantel K, et al. Effectiveness of radical systematic mediastinal lymphadenectomy in patients with resectable non-small cell lung cancer. Ann Surg. 1998; 227: 138-144.
  • 11
    Vansteenkiste JF, De Leyn PR, Deneffe GJ, et al. Clinical prognostic factors in surgically treated stage IIIA-N2 non-small cell lung cancer: analysis of the literature. Lung Cancer. 1998; 19: 3-13.
  • 12
    Keller SM, Adak S, Wagner H, et al for the Eastern Cooperative Oncology Group. Mediastinal lymph node dissection improves survival in patients with stages II and IIIa non-small cell lung cancer. Ann Thorac Surg. 2000; 70: 358-366.
  • 13
    Vansteenkiste J, Betticher D, Eberhardt W, et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small cell lung cancer. J Thorac Oncol. 2007; 2: 684-685.
  • 14
    Okada M, Nishio W, Sakamoto T, et al. Long-term survival and prognostic factors of 5-year survivors with complete resection of non-small cell lung carcinoma. J Thorac Cardiovasc Surg. 2003; 126: 558-562.
  • 15
    Andre F, Grunenwald D, Pignon JP, et al. Survival of patients with resected N2 non-small-cell lung cancer. Evidence for subclassification and implications. J Clin Oncol. 2001; 18: 2981-2989.
  • 16
    Riquet M, Bagan P, Le Pimpec Barthes F, et al. Completely resected non-small cell lung cancer: reconsidering prognostic value and significance of N2 metastases. Ann Thorac Surg. 2007; 84: 1818-1824.
  • 17
    GreeneFL, PageDL, FlemingID, et al eds. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer; 2002: 157-164.
  • 18
    Ou SH, Zell JA. Validation study of the proposed IASLC staging revisions of the T4 and M non-small cell lung cancer descriptors using data from 23,583 patients in the California Cancer Registry. J Thorac Oncol. 2008; 3: 216-227.
  • 19
    Postmus PE, Brambilla E, Chansky K, et al. The IASLC lung cancer staging project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer. J Thorac Oncol. 2007; 2: 686-693.
  • 20
    Mountain C. Revisions in the international system for staging lung cancer. Chest. 1997; 111: 1710-1717.
  • 21
    Zell JA, Ou SH, Ziogas A, Anton-Culver H. Long-term survival differences for bronchiolo-alveolar carcinoma patients with ipsilateral intrapulmonary metastasis at diagnosis. Ann Oncol. 2006; 17: 1255-1262.
  • 22
    Bryant AS, Pereira SJ, Miller DL, Cerfolio RJ. Satellite pulmonary nodule in the same lobe (T4N0) should not be staged as IIIB non-small cell lung cancer. Ann Thorac Surg. 2006; 82: 1808-1814.
  • 23
    Osaki T, Sugio K, Hanagiri T. Survival and prognostic factors of surgically resected T4 non-small cell lung cancer. Ann Thorac Surg. 2003; 75: 1745-1751.
  • 24
    Goldstraw P, Crowley J, Chansky K, et al. The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumors. J Thorac Oncol. 2007; 2: 706-714.
  • 25
    Strand TE, Rostrad H, Moller B, Norstein J. Survival after resection for primary lung cancer: a population based study of 3211 resected patients. Thorax. 2006; 61: 710-715.
  • 26
    Pfannschmidt J, Muley T, Bulzebruck H, et al. Prognostic assessment after surgical resection for non-small cell lung cancer: experiences in 2083 patients. Lung Cancer. 2006; 55: 371-377.
  • 27
    Duchateau CSJ, Stokkel MPM. Second primary tumors involving non-small cell lung cancer: prevalence and its influence on survival. Chest. 2005; 127: 1152-1158.
  • 28
    Okada M, Tsubota N, Yoshimura M, et al. Evaluation of TMN classification for lung carcinoma with ipsilateral intrapulmonary metastasis. Ann Thorac Surg. 1999; 68: 326-330.
  • 29
    Barnholtz-Sloan JS, Sloan AE, Davis FG, et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol. 2004; 22: 2865-2872.
  • 30
    Moscetti L, Nelli F, Felici A, et al. Up-front chemotherapy and radiation treatment in newly diagnosed nonsmall cell lung cancer with brain metastases: survey by Outcome Research Network for Evaluation of Treatment Results in Oncology. Cancer. 2007; 109: 274-281.
  • 31
    Burt M, Wronski M, Arbit E, et al. Resection of brain metastases from non-small-cell lung carcinoma. Results of therapy. Memorial Sloan-Kettering Cancer Center Thoracic Surgical Staff. J Thorac Cardiovasc Surg. 1992; 103: 399-410.
  • 32
    Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990; 322: 494-500.
  • 33
    Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA. 1998; 280: 1485-1489.
  • 34
    Sneed PK, Suh JH, Goetsch SJ, et al. A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases. Int J Radiat Oncol Biol Phys. 2000; 53: 519-526.
  • 35
    Chang DB, Yang PC, Luh KT, et al. Late survival of non-small cell lung cancer patients with brain metastases. Influence of treatment. Chest. 1992; 101: 1293-1297.
  • 36
    Quddus AM, Kerr GR, Price A, Gregor A. Long-term survival in patients with non-small cell lung cancer treated with palliative radiotherapy. Clin Oncol. 2001; 13: 95-98.
  • 37
    Dillman RO, Herndon J, Seagren SL, et al. Improved survival in stage III non-small-cell lung cancer: 7-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst. 1996; 88: 1210-1215.
  • 38
    Ohe Y, Ishizuka N, Tamura T, et al. Long-term follow-up of patients with unresectable locally advanced non-small cell lung cancer treated with chemoradiotherapy: a retrospective analysis of the data from the Japan Clinical Oncology Group trials (JCOG0003A). Cancer Sci. 2003; 94: 729-734.
  • 39
    Kim DW, Shyr Y, Shaktour B, et al. Long term follow up and analysis of long term survivors in patient treated with paclitaxel-based concurrent chemo/radiation therapy for locally advanced non-small cell lung cancer. Lung Cancer. 2005; 50: 235-245.
  • 40
    Janssen-Heijnen MLG, Smulders S, Lemmens VEPP, et al. Effect of comorbidity on the treatment and prognosis of elderly patients with non-small cell lung cancer. Thorax. 2004; 59: 602-607.
  • 41
    Little AG, Gay EG, Gaspar LE, Stewart AK. National survey of non-small cell lung cancer in the United States: epidemiology, pathology and patterns of care. Lung Cancer. 2007; 57: 253-260.
  • 42
    Lilenbaum RC, Cashy J, Hensing TA, et al. Prevalence of poor performance status in lung cancer patients: implications for research. J Thorac Oncol. 2008; 3: 125-134.
  • 43
    Buccieri G, Ferrigno D, Tamburini M. Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer. 1996; 32A: 1135-1141.
  • 44
    Radzikowska E, Glaz P, Roszkowski K. Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival: population-based study of 20,561 cases. Ann Oncol. 2002; 13: 1087-1093.
  • 45
    Betticher DC, Schmitz SF, Totsch M, et al. Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study. Br J Cancer. 2006; 94: 1099-1106.
  • 46
    Gandara DR, Chansky K, Albain KS, et al. Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small cell lung cancer: a phase II Southwest Oncology Group study (S9504). Clin Lung Cancer. 2006; 8: 116-121.
  • 47
    Morgensztern D, Boodgame B, Baggstrom MQ, et al. The effect of FDG-PET on the stage distribution of non-small cell lung cancer. J Thorac Oncol. 2008; 3: 135-139.
  • 48
    Mina LA, Neubauer MA, Ansari RH, et al. Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01-24/USO-023—updated results [abstract]. ASCO Meeting Abstracts. 2008; 26: 7519.
  • 49
    Perng RP, Chen CY, Chang GC, et al. Revisit of the 1997 TNM Staging System: survival analysis of 1112 lung cancer patients in Taiwan. Jpn J Clin Oncol. 2007; 37: 9-15.
  • 50
    Henschke CI, Yankelevitz DF, Miettinen OS, et al. The International Early Lung Cancer Action Program Investigators. CT screening for lung cancer: survival upon stage I diagnosis. N Engl J Med. 2006; 355: 1763-1771.